(Q50059524)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

title

Who are the long-term survivors of high grade serous ovarian cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Mark A Eckert

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Claire Hoppenot

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Samantha M Tienda

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

English

0 references

publication date

8 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

204-212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

Ten-year relative survival for epithelial ovarian cancer

2 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Clinical features of long-term survivors of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Gene expression profiles as prognostic markers in women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Surgical management of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Inherited Mutations in Women With Ovarian Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Is the NCI MATCH trial a match for gynecologic oncology?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Clinical significance of ascites in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Paraneoplastic thrombocytosis in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Improved survival in women with BRCA-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2017.10.032

10.1016/J.YGYNO.2017.10.032

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29128106%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference